Aptamer Group to host webinar and Q&A session for investors

Aptamer Group plc (LON: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, has announced that Dr Arron Tolley, Chief Executive Officer and Dr David Bunka, Chief Scientific Officer will be hosting a webinar on Thursday, 12 December 2024 at 6.00 pm (GMT).

The webinar will provide investors with a valuable opportunity to interact with Aptamer Group and gain insights into recent announcements.

There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.

You can register for the event by using the following link:

https://www.turnerpope.com/register/

We are delighted to announce that the webinar will be chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by the Company’s broker, Turner Pope Investments.

Share on:

You might also enjoy reading Aptamer licences Optimer binders for swine vaccines

Written by: Amilia Stone

Find more news, interviews, share price & company profile here for:

Latest Company News

Aptamer advances liver fibrosis therapy with targeted gene delivery

Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth.